Perrigo Current Ratio 2010-2024 | PRGO
Perrigo current ratio from 2010 to 2024. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
| Perrigo Current Ratio Historical Data | |||
|---|---|---|---|
| Date | Current Assets | Current Liabilities | Current Ratio |
| 2024-06-30 | $2.96B | $1.49B | 1.99 |
| 2024-03-31 | $2.81B | $1.56B | 1.81 |
| 2023-12-31 | $2.83B | $1.59B | 1.79 |
| 2023-09-30 | $2.77B | $1.01B | 2.74 |
| 2023-06-30 | $2.77B | $1.06B | 2.62 |
| 2023-03-31 | $2.74B | $1.09B | 2.52 |
| 2022-12-31 | $2.72B | $1.11B | 2.44 |
| 2022-09-30 | $2.58B | $1.02B | 2.55 |
| 2022-06-30 | $2.65B | $1.02B | 2.61 |
| 2022-03-31 | $3.94B | $0.98B | 4.01 |
| 2021-12-31 | $3.86B | $1.59B | 2.43 |
| 2021-09-30 | $4.23B | $2.00B | 2.11 |
| 2021-06-30 | $4.42B | $1.99B | 2.23 |
| 2021-03-31 | $4.49B | $1.45B | 3.10 |
| 2020-12-31 | $3.13B | $1.38B | 2.27 |
| 2020-09-30 | $3.40B | $1.34B | 2.54 |
| 2020-06-30 | $3.80B | $1.86B | 2.05 |
| 2020-03-31 | $3.05B | $1.64B | 1.86 |
| 2019-12-31 | $2.73B | $1.34B | 2.04 |
| 2019-09-30 | $2.74B | $1.33B | 2.07 |
| 2019-06-30 | $3.44B | $1.79B | 1.92 |
| 2019-03-31 | $3.01B | $1.83B | 1.64 |
| 2018-12-31 | $2.90B | $1.54B | 1.89 |
| 2018-09-30 | $2.77B | $1.49B | 1.85 |
| 2018-06-30 | $2.78B | $1.54B | 1.81 |
| 2018-03-31 | $2.90B | $1.39B | 2.08 |
| 2017-12-31 | $2.82B | $1.44B | 1.96 |
| 2017-09-30 | $2.97B | $1.73B | 1.72 |
| 2017-06-30 | $2.82B | $1.63B | 1.73 |
| 2017-03-31 | $5.11B | $2.49B | 2.06 |
| 2016-12-31 | $2.81B | $1.84B | 1.53 |
| 2016-09-30 | $2.62B | $1.51B | 1.73 |
| 2016-06-30 | $3.03B | $2.06B | 1.47 |
| 2016-03-31 | $3.02B | $2.22B | 1.36 |
| 2015-12-31 | $2.79B | $2.55B | 1.09 |
| 2015-09-30 | $2.88B | $1.66B | 1.73 |
| 2015-06-30 | $3.18B | $1.69B | 1.88 |
| 2015-03-31 | $5.13B | $1.28B | 4.00 |
| 2014-12-31 | $5.36B | $1.33B | 4.05 |
| 2014-09-30 | $2.63B | $1.02B | 2.59 |
| 2014-06-30 | $2.55B | $1.08B | 2.37 |
| 2014-03-31 | $2.30B | $0.95B | 2.42 |
| 2013-12-31 | $2.29B | $0.96B | 2.38 |
| 2013-09-30 | $2.37B | $0.74B | 3.18 |
| 2013-06-30 | $2.24B | $0.75B | 2.99 |
| 2013-03-31 | $1.70B | $0.67B | 2.52 |
| 2012-12-31 | $1.77B | $0.64B | 2.79 |
| 2012-09-30 | $1.90B | $0.63B | 3.02 |
| 2012-06-30 | $1.80B | $0.65B | 2.75 |
| 2012-03-31 | $1.79B | $0.63B | 2.84 |
| 2011-12-31 | $1.73B | $0.67B | 2.60 |
| 2011-09-30 | $1.30B | $0.62B | 2.09 |
| 2011-06-30 | $1.38B | $0.61B | 2.27 |
| 2011-03-31 | $1.26B | $0.57B | 2.22 |
| 2010-12-31 | $1.16B | $0.59B | 1.98 |
| 2010-09-30 | $1.02B | $0.57B | 1.78 |
| 2010-06-30 | $1.40B | $0.92B | 1.52 |
| 2010-03-31 | $1.15B | $0.45B | 2.53 |
| 2009-12-31 | $1.16B | $0.49B | 2.39 |
| 2009-09-30 | $1.10B | $0.46B | 2.40 |
| 2009-06-30 | $1.15B | $0.50B | 2.30 |
| 2009-03-31 | $1.04B | $0.44B | 2.37 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $3.496B | $4.656B |
| Perrigo Co. plc, with a diversified revenue stream, sells infant formulas for the store brand market, generic extended topical prescription (Rx) products and specialty pharmaceutical drugs. It's focusing on self-care products as part of its transformation into a self-care company from a healthcare company. The company divested its Rx segment to Altaris Capital Partners. The company completed its transformation to a consumer self-care company by reconfiguring the portfolio through the divestiture of RX business. Currently, the company has 2 reporting segments. Consumer Self Care Americas (CSCA): The segment comprises the U.S., Mexico and Canada CHC business, including OTC, contract manufacturing, infant formula and animal health categories. Consumer Self Care International?(CSCI): The segment comprises the branded consumer healthcare (BCH) segment mainly in Europe and the company's consumer-focused businesses in the UK and Australia. This segment includes UK liquids licensed products business. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $196.139B | 25.33 |
| Stryker (SYK) | United States | $137.702B | 32.18 |
| Boston Scientific (BSX) | United States | $122.346B | 37.26 |
| Medtronic (MDT) | Ireland | $114.719B | 17.07 |
| EssilorLuxottica (ESLOY) | France | $106.985B | 0.00 |
| Haleon (HLN) | United Kingdom | $48.286B | 35.30 |
| Lonza Group Ag (LZAGY) | Switzerland | $46.218B | 0.00 |
| ResMed (RMD) | United States | $35.640B | 31.38 |
| Koninklijke Philips (PHG) | Netherlands | $29.674B | 22.55 |
| Terumo (TRUMY) | Japan | $28.204B | 39.83 |
| Zimmer Biomet Holdings (ZBH) | United States | $21.935B | 13.81 |
| Baxter (BAX) | United States | $19.749B | 13.39 |
| Insulet (PODD) | United States | $16.507B | 69.45 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $13.465B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $9.256B | 30.67 |
| Demant (WILYY) | Denmark | $8.667B | 0.00 |
| BellRing Brands (BRBR) | United States | $7.864B | 33.25 |
| Lantheus Holdings (LNTH) | United States | $7.251B | 17.41 |
| ICU Medical (ICUI) | United States | $4.262B | 40.67 |
| Haemonetics (HAE) | United States | $3.918B | 19.38 |
| Neogen (NEOG) | United States | $3.612B | 37.89 |
| TG Therapeutics (TGTX) | United States | $3.612B | 38.25 |
| GN Store Nord (GNNDY) | Denmark | $3.576B | 21.54 |
| Prestige Consumer Healthcare (PBH) | United States | $3.536B | 17.62 |
| Envista Holdings (NVST) | United States | $3.310B | 17.66 |
| QuidelOrtho (QDEL) | United States | $2.970B | 18.72 |
| Agios Pharmaceuticals (AGIO) | United States | $2.734B | 0.00 |
| Green Thumb Industries (GTBIF) | United States | $2.220B | 37.25 |
| Maravai LifeSciences Holdings (MRVI) | United States | $2.109B | 0.00 |
| LeMaitre Vascular (LMAT) | United States | $2.029B | 54.07 |
| Warby Parker (WRBY) | United States | $1.620B | 0.00 |
| InMode (INMD) | Israel | $1.444B | 9.19 |
| AdaptHealth (AHCO) | United States | $1.385B | 10.00 |
| AtriCure (ATRC) | United States | $1.384B | 0.00 |
| Owens & Minor (OMI) | United States | $1.213B | 9.36 |
| Verano Holdings (VRNOF) | United States | $1.199B | 0.00 |
| BioLife Solutions (BLFS) | United States | $1.115B | 0.00 |
| Evolus (EOLS) | United States | $1.032B | 0.00 |
| PetIQ (PETQ) | United States | $0.919B | 23.29 |
| Phibro Animal Health (PAHC) | United States | $0.895B | 18.57 |
| National Vision Holdings (EYE) | United States | $0.852B | 27.10 |
| Cresco Labs (CRLBF) | United States | $0.820B | 0.00 |
| Surmodics (SRDX) | United States | $0.549B | 116.58 |
| Quanterix (QTRX) | United States | $0.498B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.483B | 14.57 |
| ZimVie (ZIMV) | United States | $0.430B | 39.97 |
| Valneva SE (VALN) | France | $0.425B | 0.00 |
| Jin Medical (ZJYL) | China | $0.422B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.397B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.386B | 0.00 |
| Cerus (CERS) | United States | $0.330B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.325B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.318B | 8.19 |
| Aurora Cannabis (ACB) | Canada | $0.314B | 0.00 |
| Biote (BTMD) | United States | $0.295B | 13.62 |
| Viemed Healthcare (VMD) | United States | $0.281B | 30.17 |
| Zynex (ZYXI) | United States | $0.262B | 45.89 |
| Sanara MedTech (SMTI) | United States | $0.254B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.233B | 15.45 |
| Omeros (OMER) | United States | $0.227B | 0.00 |
| Organigram Holdings (OGI) | Canada | $0.192B | 0.00 |
| MacroGenics (MGNX) | United States | $0.191B | 0.00 |
| Ayr Wellness (AYRWF) | United States | $0.191B | 0.00 |
| High Tide (HITI) | Canada | $0.157B | 65.00 |
| FitLife Brands (FTLF) | United States | $0.152B | 20.55 |
| Brainsway (BWAY) | Israel | $0.137B | 164.20 |
| TriSalus Life Sciences (TLSI) | United States | $0.122B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.122B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.117B | 0.00 |
| Veru (VERU) | United States | $0.114B | 0.00 |
| Fonar (FONR) | United States | $0.112B | 11.39 |
| Jushi Holdings (JUSHF) | United States | $0.105B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.098B | 24.00 |
| Zevia PBC (ZVIA) | United States | $0.085B | 0.00 |
| InterCure (INCR) | Israel | $0.083B | 14.08 |
| Cytosorbents (CTSO) | United States | $0.077B | 0.00 |
| Modular Medical (MODD) | United States | $0.077B | 0.00 |
| Safety Shot (SHOT) | United States | $0.072B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.068B | 0.00 |
| MariMed (MRMD) | United States | $0.065B | 0.00 |
| Exagen (XGN) | United States | $0.055B | 0.00 |
| Eagle Pharmaceuticals (EGRX) | United States | $0.053B | 3.44 |
| Allurion Technologies (ALUR) | United States | $0.041B | 0.00 |
| Apyx Medical (APYX) | United States | $0.041B | 0.00 |
| ImmuCell (ICCC) | United States | $0.028B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.026B | 0.00 |
| Nephros (NEPH) | United States | $0.019B | 0.00 |
| Flora Growth (FLGC) | United States | $0.017B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.014B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.013B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.009B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.008B | 0.00 |
| GUARDION HEALTH (GHSI) | United States | $0.007B | 0.00 |
| Agape ATP (ATPC) | $0.007B | 0.00 | |
| Leafly Holdings (LFLY) | United States | $0.006B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.005B | 0.00 |
| Sharps Technology (STSS) | United States | $0.005B | 0.00 |
| Senestech (SNES) | United States | $0.001B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.001B | 0.00 |
| Akanda (AKAN) | United Kingdom | $0.000B | 0.00 |
| United-Guardian (UG) | United States | $0.000B | 21.89 |
| SNDL (SNDL) | Canada | $0.000B | 0.00 |